GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Isatuximab overview

Isatuximab (Sarclisa) is a monoclonal antibody acts as anticancer agent. It is formulated as solution and concentrate for solution for intravenous route of administration. Sarclisa is indicated for treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, and relapsed or refractory multiple myeloma.

Isatuximab (SAR650984) is under development for the treatment of relapsed or refractory natural killer cell lymphoma, T-cell lymphomas, AL amyloidosis, pediatric patients for the treatment of relapsed/refractory acute lymphoblastic leukemia and relapsed/refractory acute myeloid leukemia, hematological malignancies including B-cell non-Hodgkin-lymphoma/leukemia (NHL), metastatic colorectal cancer, chronic lymphocytic leukemia (CLL), plasma cell myeloma, smoldering multiple myeloma and relapsed and refractory multiple myeloma. It is administered through intravenous and subcutaneous routes. The drug candidate is a naked humanized monoclonal antibody targeting CD38 antigen. It is a new molecular entity (NME). It was also under development for the treatment of non-small cell lung cancer, metastatic castration-resistant prostate cancer, as a third line therapy for recurrent metastatic squamous cell carcinoma of the head and neck (SCCHN), diffuse large b-cell lymphoma, peripheral T-cell lymphoma, mantle cell lymphoma, acute lymphoblastic lymphoma and refractory immune cytopenias.

It was also under development for the treatment of classic Hodgkin's lymphoma, hepatocellular carcinoma (HCC), recurrent glioblastoma multiforme (GBM) and epithelial ovarian cancer (EOC), oral cavity, T-cell acute lymphoblastic leukemia (T-ALL), acute myeloid leukemia (AML), oropharyngeal cancer, laryngeal cancer, autoimmune hemolytic anemia.

Sanofi overview

Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, multiple sclerosis; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals, and supplements. Sanofi‘s R&D efforts focus on advancing a combination drug to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has an operational presence in Europe, the Americas, Africa, Asia-Pacific, and the Middle East. Sanofi is headquartered in Paris, Ile-de-France, France.

For a complete picture of Isatuximab’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.